ENDRA Life Sciences reported Q3 2024 financial results with a net loss of $2.4M, compared to $3.1M in Q3 2023. Operating expenses decreased 52% YoY to $1.5M, primarily due to reduced general and administrative spending. The company ended the quarter with $4.7M in cash.The company made significant progress in its clinical initiatives, accelerating subject recruitment with nearly 40 subjects enrolled or being scanned in the past two months. ENDRA activated a TAEUS system at LMU University Hospital in Germany for post-market clinical study and expanded its patent portfolio to 82 issued patents globally.Management implemented cost-cutting measures, achieving $3.1M in annualized savings while refocusing resources on clinical and regulatory activities to support future FDA De Novo submission. The company also advanced its TAEUS platform by introducing new AI and machine learning features to improve data accuracy and operator ease-of-use.

ENDRA Life Sciences reported Q3 2024 financial results with a net loss of $2.4M, compared to $3.1M in Q3 2023. Operating expenses decreased 52% YoY to $1.5M, primarily due to reduced general and administrative spending. The company ended the quarter with $4.7M in cash.The company made significant progress in its clinical initiatives, accelerating subject recruitment with nearly 40 subjects enrolled or being scanned in the past two months. ENDRA activated a TAEUS system at LMU University Hospital in Germany for post-market clinical study and expanded its patent portfolio to 82 issued patents globally.Management implemented cost-cutting measures, achieving $3.1M in annualized savings while refocusing resources on clinical and regulatory activities to support future FDA De Novo submission. The company also advanced its TAEUS platform by introducing new AI and machine learning features to improve data accuracy and operator ease-of-use.